Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
|Podcasts|March 21, 2023
Health Equity Conversations: Improving Diversity of Oncology Care Staff
Author(s)Matthew Gavidia
On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.
Advertisement
AJMC.com recently launched a resource center, the
On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion (DEI) advancing health equity in their respective organization’s policy and practice initiatives, including:
- Terrance Mayes, EdD, associate director for DEI at the Stanford Cancer Institute, and inaugural chair of National Comprehensive Cancer Network's (NCCN) DEI Directors Forum
- Loretta Erhunmwunsee, MD, FACS, thoracic surgeon and an assistant professor in the Division of Thoracic Surgery, City of Hope National Medical Center, and inaugural vice-chair of NCCN's DEI Directors Forum
- Richard L. Martin III, MD, MPH, medical director for Health Equity and Community Engagement, Tennessee Oncology; president, Tennessee Oncology Practice Society.
Advertisement
Related to this article
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
Advertisement
Advertisement